companydata.dkcompanydata.dk

AGC Biologics A/S: Financial statements 2018

CVR: 25950941

Source: annual report 2018, Danish Business Authority

01/01/2018 – 31/12/2018

AGC Biologics A/S (CVR 25950941) has filed annual accounts for 2018. In 2018, the company reported revenue of DKK 692,613,000 and a net result of DKK 96,167,000 compared with DKK 74,528,000 the year before. That is an increase of 7.6% compared with the year before. The profit margin was 13.9%. Equity in the 2018 report amounted to DKK 316,811,000. The solvency ratio was 49.9%. The company had 312 employees in the financial year.

Revenue
DKK 692,613,000
Gross Profit
DKK 162,263,000
Profit/Loss
DKK 96,167,000
Equity
DKK 316,811,000
Total Assets
DKK 634,585,000
Employees
312

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2018692.6M162.3M96.2M316.8M312
2017643.6M156.8M74.5M290.6M303
2016521.8M116.1M68.2M216.1M245
2015320.5M62.3M8.4M147.9M209
2014311.1M45.8M3.2M139.5M199

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2018

CMC BIOLOGICS A/S changes name to AGC Biologics A/SNov 30, 2018

On November 30, 2018, the company changed its name from CMC BIOLOGICS A/S to AGC Biologics A/S.

Hideyuki Kurata joins the board of AGC Biologics A/SOct 3, 2018

As of October 3, 2018, Hideyuki Kurata has joined the board of directors of AGC Biologics A/S.

Noriyuki Komuro joins the board of AGC Biologics A/SOct 3, 2018

As of October 3, 2018, Noriyuki Komuro has joined the board of directors of AGC Biologics A/S.

Hideyuki Kurata leaves the board of AGC Biologics A/SOct 2, 2018

As of October 2, 2018, Hideyuki Kurata has left the board of directors of AGC Biologics A/S.

Noriyuki Komuro leaves the board of AGC Biologics A/SOct 2, 2018

As of October 2, 2018, Noriyuki Komuro has left the board of directors of AGC Biologics A/S.

Noriyuki Komuro joins the board of AGC Biologics A/SSep 17, 2018

As of September 17, 2018, Noriyuki Komuro has joined the board of directors of AGC Biologics A/S.

Yukiteru Nakashita leaves the board of AGC Biologics A/SAug 31, 2018

As of August 31, 2018, Yukiteru Nakashita has left the board of directors of AGC Biologics A/S.

AGC Biologics A/S: The 2017 annual report is outJun 6, 2018

AGC Biologics A/S has published its annual report for 2017. Revenue came to DKK 643,563,000, and the net result was DKK 74,528,000.

Hiroshi Nishimura joins the board of AGC Biologics A/SJan 31, 2018

As of January 31, 2018, Hiroshi Nishimura has joined the board of directors of AGC Biologics A/S.

Masahiko Fukamachi leaves the board of AGC Biologics A/SJan 31, 2018

As of January 31, 2018, Masahiko Fukamachi has left the board of directors of AGC Biologics A/S.

About AGC Biologics A/S

AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,503 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.

Source: annual report 2025, Danish Business Authority